You produced another masterpiece, congratulations.
I would only like to point out that 770 will also be used together with developing correctors. In the next 5-10 years correctors such as 809, 661, or competitor drugs will be developed to treat 508 CFers. Since correctors need 770 to potentiate CFTR, the market for 770 will expand to treat 70% of all CFers as well. This means that the market for 770 will expand 1750% as soon as a corrector becomes available. 770 merits a high multiple.